19:23 , Jun 20, 2018 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: Tissue markers Low esophageal levels of SPINK7 could help diagnose eosinophilic esophagitis. In esophageal tissue samples, SPINK7 protein and mRNA levels were lower in patients with eosinophilic esophagitis than in healthy volunteers, and the...
23:29 , Apr 13, 2018 |  BioCentury  |  Tools & Techniques

Personalizing prevention

PlaqueTec Ltd. is working to bring personalized medicine to the cardiovascular space with a device that samples local concentrations of molecules near atherosclerotic plaques. By using these samples to identify prognostic and predictive biomarkers, the...
21:56 , Jan 5, 2018 |  BC Week In Review  |  Clinical News

Foresee reports Phase I data for asthma/COPD candidate

Foresee Pharmaceuticals Co. Ltd. (TPEx-E:6576) reported data from a pair of double-blind Phase I trials in healthy volunteers showing that asthma and chronic obstructive pulmonary disease (COPD) candidate FP-025 was generally well tolerated with no...
07:00 , Jul 31, 2014 |  BC Innovations  |  Translation in Brief

Translational tidbits

Benjamin Boettner, Associate Editor, and Chris Cain, Michael J. Haas and Kai-Jye Lou, Senior Writers  Quantitative boost for CSHL The Simons Foundation has donated $50 million to Cold Spring Harbor Laboratory to establish the Simons...
07:00 , Jun 28, 2012 |  BC Innovations  |  Strategy

Pharma compounds at the crossroads

The National Center for Advancing Translational Sciences (NCATS) has disclosed details about the first library of therapeutics in its Discovering New Therapeutic Uses for Existing Molecules program ( see "Repurposing pharma compounds"). The compounds provided...
08:00 , Feb 17, 2011 |  BC Innovations  |  Targets & Mechanisms

EMMPRIN's new clothes

EMMPRIN dropped off the drug discovery map in 2003 when Abgenix Inc. 's antibody against the target failed in a Phase II/III trial to treat graft-versus-host disease. Now, findings from Canadian researchers suggest it might...
07:00 , Aug 27, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Inflammation

Indication Target/marker/pathway Summary Licensing status Publication and contact nformation Inflammation Asthma Matrix metalloproteinase 12 (MMP12) An SAR study identified a series of MMP12 inhibitors that could be useful for treating asthma. In a sheep model...
07:00 , Jul 9, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Bacterial infection Matrix metalloproteinase 12 (macrophage elastase) (MMP12) In vitro and mouse studies suggest that targeting MMP12 could help treat bacterial infection. In mice...
07:00 , Mar 26, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Pulmonary disease

This week in therapeutics Indication Target/marker/ pathway Summary Licensing status Publication and contact information Pulmonary disease Chronic obstructive pulmonary disease (COPD) Matrix metalloproteinase 12 (MMP12) An SAR study identified a series of MMP12 inhibitors that...
07:00 , Jun 12, 2008 |  BC Innovations  |  Distillery Therapeutics

This Week in Therapeutics

This week in therapeutics Indication Target/ marker/pathway Summary Licensing status Publication and contact information Pulmonary disease Chronic obstructive pulmonary disease (COPD); emphysema Matrix metalloproteinase 12 (MMP12) An in vitro screen identified a series of MMP12...